Chembio takes rapid HIV tests to the US

This article was originally published in Clinica

09 Jun 2006
News

Executive Summary

Paving its entry into the lucrative US HIV testing market, Chembio Diagnostics has gained FDA approval for its rapid HIV tests. Clearance of its Sure Check HIV 1/2 and HIV 1/2 Stat-Pak tests will allow the company to tap into a US rapid HIV test professional market that it believes will exceed $50m within the next couple of years. Chembio is currently in discussions with a partner to market the products in the US.

Already Registered? Sign in to continue reading.

New to Medtech Insight? Start a free trial today!

Table
View full table

Topics

Industries
Medical Device

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

Medical Device

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

MT051892

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

MT051892

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Chembio takes rapid HIV tests to the US

News

Executive Summary

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert